Zai Lab to Present First Clinical Trial Data on ZL-1503
Zai Lab says data from the first clinical trial of its internally developed IL-13/IL-31Rα bispecific antibody will be shared for the first time at the American College of Allergy, Asth…
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Zai Lab to present Phase 1/1b healthy — volunteer data for atopic disease antibody ZL — 1503 at ACAAI 2026
Zai Lab flagged first clinical data for ZL-1503, a bispecific antibody for atopic diseases, from its Phase 1/1b healthy-volunteer trial. Results have not been presented yet; the initial readout is scheduled for the ACAAI 2026 meeting on Nov. 13. The update will cover how the drug behaved in the body, early biomarker ef
Zai Lab to Present Data From First Clinical Trial Evaluating ZL — 1503, an IL — 13/IL — 31Rα Bispecific Antibody, for Atopic Diseases
For best results when printing this announcement, please click on link below: Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases - Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting